v3.25.3

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Current assets:
Cash	$ 381	$ 454
Accounts receivable, net	405	522
Inventory	4,080	4,897
Prepaid expenses and other	231	370
Total current assets	5,097	6,243
Property and equipment, net	349	399
Right of use assets	410	94
Intangibles, net	82	93
Goodwill	1,010	971
Other assets	47	127
Total assets	6,995	7,927
Current liabilities:
Accounts payable	1,214	1,925
Accrued expenses	2,874	3,424
Current portion of operating lease liability	247	83
Current portion of long-term debt, net of debt issuance costs	451	677
Total current liabilities	4,786	6,109
Operating lease liability	162	19
Debt, net of debt issuance costs	504	0
Deferred tax liability	4	4
Total liabilities	5,456	6,132
Commitments and contingencies (Note 10)
Stockholders' equity
Preferred stock, par value $0.0001; 10,000 shares authorized; 1 share issued as of September 30, 2025 and December 31, 2024; and no shares outstanding as of September 30, 2025 and December 31, 2024
Common stock, par value $0.0001; 790,000 shares authorized as of September 30, 2025 and December 31, 2024; 184,264 shares issued and outstanding as of September 30, 2025 and December 31, 2024	18	18
Additional paid-in capital	89,207	88,773
Accumulated deficit	(87,733)	(86,981)
Accumulated other comprehensive income (loss)	47	(15)
Total stockholders' equity	1,539	1,795
Total liabilities and stockholders' equity	$ 6,995	$ 7,927

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

CV Sciences, Inc. 10-Q